Literature DB >> 23523787

The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer.

Junjie Wang1, Lili Yu, Jing Cai, Jinghui Jia, Yanping Gao, Minglin Liang, Zehua Wang.   

Abstract

Enhancer of zeste homolog 2 (EZH2) is overexpressed in various malignancies and associated with poor prognosis and drug-resistance. A recent study suggested that there is a link between EZH2 expression and the mediation of gene silencing in association with aberrant DNA methylation. In the present study, we showed an inverse correlation between EZH2 and human mutL homolog 1 gene (hMLH1) expression in 30 epithelial ovarian cancer (EOC) tissues. Moreover, we found that EZH2 downregulation could induce the re-expression of the unmethylated, basally expressed hMLH1 gene without affecting DNA methylation in the hMLH1 promoter. These results suggest that EZH2 can modulate the transcription of basally expressed hMLH1 via a non-DNA-methylation-dependent pathway, but it has no effect on hMLH1 silencing that is mediated by DNA hypermethylation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23523787     DOI: 10.1016/j.bbrc.2013.03.037

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.

Authors:  Fang Wu; Min Lu; Lu Qu; Dai-Qiang Li; Chun-Hong Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 2.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

3.  miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation.

Authors:  Wei Zhang; Jo-Hsin Chen; Tianjiao Shan; Irene Aguilera-Barrantes; Li-Shu Wang; Tim Hui-Ming Huang; Janet S Rader; Xiugui Sheng; Yi-Wen Huang
Journal:  Lab Invest       Date:  2018-06-28       Impact factor: 5.662

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.